Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms ERD-856 |
Target |
Action degraders |
Mechanism ERα degraders(Estrogen receptor alpha degraders) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC46H45N5O6 |
InChIKeyJSLJXCMFGCYXEV-HJNPNHQXSA-N |
CAS Registry- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Estrogen receptor positive breast cancer | Preclinical | United States | 30 Aug 2023 |





